Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Anorexia Nervosa01:28

Anorexia Nervosa

Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study.

International journal of clinical oncology·2026
Same author

Characteristics and reasons for low-dose fentanyl patch use in opioid-naïve versus non-naïve patients with cancer pain.

Japanese journal of clinical oncology·2026
Same author

Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category, Observed Body Weight, and Prognostic Nutritional Index.

Journal of palliative medicine·2026
Same author

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Can Naldemedine Allow Higher Oxycodone Dosing in Patients with Cancer? A Single-Center Retrospective Study.

Journal of palliative medicine·2026
Same author

High-Dose Intravenous Ferric Carboxymaltose/Derisomaltose Without ESAs for Cancer-Related Anemia in Japan: A Retrospective Single-Center Cohort Study.

Cancers·2026

Related Experiment Video

Updated: May 15, 2026

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
10:52

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis

Published on: December 17, 2010

Autoimmune polyglandular syndrome type 3 with anorexia.

Toshio Kahara1, Hitomi Wakakuri, Juri Takatsuji

  • 1Department of Internal Medicine, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan.

Case Reports in Endocrinology
|January 11, 2013
PubMed
Summary
This summary is machine-generated.

A 71-year-old man with autoimmune polyglandular syndrome type 3 presented with weight loss and was diagnosed with pernicious anemia and slowly progressive type 1 diabetes mellitus. Early cobalamin replacement is crucial to prevent irreversible neurological complications.

More Related Videos

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Experiment Videos

Last Updated: May 15, 2026

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis
10:52

Preparation of Mouse Pituitary Immunogen for the Induction of Experimental Autoimmune Hypophysitis

Published on: December 17, 2010

Isolation of Human Islets from Partially Pancreatectomized Patients
11:10

Isolation of Human Islets from Partially Pancreatectomized Patients

Published on: July 30, 2011

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Neurology

Background:

  • Autoimmune polyglandular syndrome (APS) is a rare disorder characterized by autoimmune-mediated dysfunction of multiple endocrine glands.
  • Pernicious anemia (PA) and type 1 diabetes mellitus (T1DM) are autoimmune conditions that can occur independently or as part of APS.
  • Slowly progressive type 1 diabetes mellitus (SPIDDM) is a variant of T1DM with a gradual onset, often presenting in adulthood.

Purpose of the Study:

  • To report a rare case of autoimmune polyglandular syndrome type 3 (APS-3) presenting with pernicious anemia (PA) and slowly progressive type 1 diabetes mellitus (SPIDDM).
  • To highlight the importance of early diagnosis and treatment of cobalamin deficiency in patients with autoimmune diseases to prevent irreversible neurological damage.
  • To emphasize the need for considering PA in diabetic patients with unexplained anorexia and macrocytosis.

Main Methods:

  • Case report of a 71-year-old male patient.
  • Clinical evaluation including history, physical examination, and laboratory tests (cobalamin levels, autoantibodies).
  • Diagnostic workup for anemia, diabetes mellitus, and autoimmune conditions.

Main Results:

  • The patient presented with anorexia, significant weight loss, and megaloblastic anemia.
  • Laboratory findings revealed low cobalamin levels, positive intrinsic factor autoantibody, GAD autoantibody, ICA, and thyroid autoantibodies.
  • Diagnosis of APS-3 with SPIDDM, PA, and Hashimoto's thyroiditis was established. Treatment with intramuscular cyanocobalamin improved his appetite.

Conclusions:

  • This case underscores the rare co-occurrence of APS-3, PA, and SPIDDM.
  • Prompt recognition and management of cobalamin deficiency are vital to avert potentially irreversible neurological sequelae like ataxia and dementia.
  • Physicians should maintain a high index of suspicion for PA in diabetic patients exhibiting unexplained anorexia and macrocytosis.